By using CTLA-4 antibodies, it is possible to block the binding of CTLA-4 to CD80/CD86, weakening the inhibition of T cell activation and enhancing the role of the immune system against lung cancer (26). This evidence concerns the gene CTLA4 and lung carcinoma.